Ajovy (Fremanezumab)
fremanezumab 225 mg/1.5 mL injection, 1.5 mL syringe · INJECTION · PBS code 12603H
STREAMLINEDWhat it costs
AU$488.89 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2021-08-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Treatment-resistant migraine
Continuing treatment
Must be treated by a neurologist; or
Must be treated by a general practitioner in consultation with a neurologist; AND
Patient must not be undergoing concurrent treatment with the following PBS benefits: (i) botulinum toxin type A listed for this PBS indication, (ii) another drug in the same pharmacological class as this drug listed for this PBS indication; AND
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Patient must have achieved and maintained at least 50% reduction from baseline in the number of migraine headache days per month; AND
Patient must continue to be appropriately managed for medication overuse headache.
Patient must have the number of migraine headache days per month documented in their medical records.
Sponsor: Teva Pharma Australia Pty Ltd ABN 41 169 715 664
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.